RHOEN-KLINIKUM AG (RHK.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:RHK - DE0007042301 - Common Stock
12.7 EUR
-0.2 (-1.55%)
Taking everything into account, RHK scores 4 out of 10 in our fundamental rating. RHK was compared to 28 industry peers in the Health Care Providers & Services industry. While RHK has a great health rating, there are worries on its profitability. While showing a medium growth rate, RHK is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
RHK had positive earnings in the past year.
In the past year RHK had a positive cash flow from operations.
RHK had positive earnings in each of the past 5 years.
RHK had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 2.02%, RHK is doing worse than 60.71% of the companies in the same industry.
The Return On Equity of RHK (2.90%) is worse than 67.86% of its industry peers.
RHK has a worse Return On Invested Capital (2.67%) than 75.00% of its industry peers.
RHK had an Average Return On Invested Capital over the past 3 years of 2.34%. This is below the industry average of 6.91%.
The last Return On Invested Capital (2.67%) for RHK is above the 3 year average (2.34%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROIC | 2.67% |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
1.3 Margins
With a Profit Margin value of 2.28%, RHK is not doing good in the industry: 60.71% of the companies in the same industry are doing better.
In the last couple of years the Profit Margin of RHK has declined.
Looking at the Operating Margin, with a value of 2.86%, RHK is doing worse than 71.43% of the companies in the same industry.
RHK's Operating Margin has declined in the last couple of years.
The Gross Margin of RHK (66.81%) is better than 75.00% of its industry peers.
RHK's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% |
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RHK is destroying value.
RHK has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for RHK remains at a similar level compared to 5 years ago.
RHK has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.06 indicates that RHK is not in any danger for bankruptcy at the moment.
RHK has a better Altman-Z score (3.06) than 78.57% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that RHK is not too dependend on debt financing.
The Debt to Equity ratio of RHK (0.09) is better than 92.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.06 |
ROIC/WACC0.41
WACC6.47%
2.3 Liquidity
RHK has a Current Ratio of 2.28. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
RHK's Current ratio of 2.28 is amongst the best of the industry. RHK outperforms 92.86% of its industry peers.
A Quick Ratio of 2.19 indicates that RHK has no problem at all paying its short term obligations.
RHK's Quick ratio of 2.19 is amongst the best of the industry. RHK outperforms 92.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 |
3. Growth
3.1 Past
The earnings per share for RHK have decreased strongly by -15.41% in the last year.
Measured over the past 5 years, RHK shows a small growth in Earnings Per Share. The EPS has been growing by 0.03% on average per year.
RHK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.10%.
The Revenue has been growing slightly by 4.12% on average over the past years.
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
3.2 Future
RHK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.89% yearly.
RHK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.24% yearly.
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.89%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y6.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 22.28, RHK is valued on the expensive side.
Based on the Price/Earnings ratio, RHK is valued a bit more expensive than 60.71% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. RHK is around the same levels.
The Price/Forward Earnings ratio is 16.62, which indicates a correct valuation of RHK.
The rest of the industry has a similar Price/Forward Earnings ratio as RHK.
The average S&P500 Price/Forward Earnings ratio is at 23.13. RHK is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.28 | ||
| Fwd PE | 16.62 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RHK indicates a rather cheap valuation: RHK is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.26 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)5.18
PEG (5Y)655.19
EPS Next 2Y10.47%
EPS Next 3Y11.09%
5. Dividend
5.1 Amount
RHK has a yearly dividend return of 0.77%, which is pretty low.
Compared to an average industry Dividend Yield of 1.47, RHK has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.00, RHK's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.77% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
17.78% of the earnings are spent on dividend by RHK. This is a low number and sustainable payout ratio.
DP17.78%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
FRA:RHK (12/30/2025, 7:00:00 PM)
12.7
-0.2 (-1.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap850.39M
Revenue(TTM)1.69B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (13.78%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.77% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.43%
EPS NY rev (3m)-4.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)0.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.28 | ||
| Fwd PE | 16.62 | ||
| P/S | 0.51 | ||
| P/FCF | N/A | ||
| P/OCF | 13.78 | ||
| P/B | 0.65 | ||
| P/tB | 0.76 | ||
| EV/EBITDA | 0.26 |
EPS(TTM)0.57
EY4.49%
EPS(NY)0.76
Fwd EY6.02%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.26%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)5.18
PEG (5Y)655.19
Graham Number15.78
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROCE | 3.25% | ||
| ROIC | 2.67% | ||
| ROICexc | 4.45% | ||
| ROICexgc | 5.55% | ||
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% | ||
| FCFM | N/A |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.07 | ||
| Cap/Depr | 112.99% | ||
| Cap/Sales | 4.21% | ||
| Interest Coverage | 14.78 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 | ||
| Altman-Z | 3.06 |
F-Score6
WACC6.47%
ROIC/WACC0.41
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.89%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y6.24%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y28.34%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%
RHOEN-KLINIKUM AG / RHK.DE FAQ
Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?
ChartMill assigns a fundamental rating of 4 / 10 to RHK.DE.
What is the valuation status of RHOEN-KLINIKUM AG (RHK.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.
Can you provide the profitability details for RHOEN-KLINIKUM AG?
RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 3 / 10.
Can you provide the financial health for RHK stock?
The financial health rating of RHOEN-KLINIKUM AG (RHK.DE) is 7 / 10.
How sustainable is the dividend of RHOEN-KLINIKUM AG (RHK.DE) stock?
The dividend rating of RHOEN-KLINIKUM AG (RHK.DE) is 2 / 10 and the dividend payout ratio is 17.78%.